Clinical decision-support only. For use by licensed dental professionals. Not a substitute for professional judgment or a complete drug reference. Always verify with primary sources.
← Back to search
Medication

Capecitabine

Antineoplastic (oral 5-FU prodrug)

Brand names: Xeloda

Oral health effects

  • Oral mucositis

    Painful, ulcerative inflammation of the oral mucosa that can limit nutrition and serve as a portal for infection.

    Mechanism: Direct cytotoxic injury to rapidly dividing mucosal epithelium.

    Clinical management: Pre-treatment dental clearance, basic oral care protocols, bland rinses, topical analgesia; oncology coordination. Cryotherapy helps with some bolus regimens.

  • Infection & bleeding risk (myelosuppression)

    Neutropenia and thrombocytopenia raise the risk of oral infection and bleeding.

    Clinical management: Defer elective invasive care during neutropenic/thrombocytopenic nadirs; coordinate counts with oncology.

  • Taste change (dysgeusia)

    Taste disturbance was reported in 14–16% of patients in label clinical-trial tables.

    Clinical management: Reassure that taste changes are common during cancer therapy and usually improve after treatment; rule out oral candidiasis and dry mouth, keep the mouth clean (bland rinses), and suggest dietitian input if eating is affected.

Sources

  1. MASCC/ISOO clinical practice guidelines for the management of mucositis. Lalla RV, Bowen J, et al.. Cancer, 2014.
  2. Capecitabine prescribing information (FDA label) Quallent Pharmaceuticals Health LLC / DailyMed, 2025.
  3. A systematic review of dysgeusia induced by cancer therapies. Hovan AJ, Williams PM, Stevenson-Moore P, et al. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2010.